Q2 2024 EPS Estimates for Sanofi (NASDAQ:SNY) Cut by Leerink Partnrs

Sanofi (NASDAQ:SNY) – Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for Sanofi in a research report issued to clients and investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.93. The consensus estimate for Sanofi’s current full-year earnings is $4.15 per share. Leerink Partnrs also issued estimates for Sanofi’s Q3 2024 earnings at $1.30 EPS, Q4 2024 earnings at $0.82 EPS, FY2026 earnings at $4.78 EPS and FY2027 earnings at $5.00 EPS.

SNY has been the topic of a number of other research reports. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Stock Up 2.0 %

Sanofi stock opened at $46.30 on Friday. The firm has a market cap of $117.12 billion, a price-to-earnings ratio of 19.62, a price-to-earnings-growth ratio of 1.57 and a beta of 0.61. Sanofi has a 52 week low of $42.63 and a 52 week high of $57.82. The business’s 50-day moving average price is $47.52 and its 200 day moving average price is $48.58. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%.

Hedge Funds Weigh In On Sanofi

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Boston Partners lifted its position in shares of Sanofi by 1.9% in the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after acquiring an additional 245,682 shares in the last quarter. BlackRock Inc. lifted its position in shares of Sanofi by 2.5% in the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock valued at $546,804,000 after acquiring an additional 249,619 shares in the last quarter. Morgan Stanley lifted its position in shares of Sanofi by 19.3% in the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock valued at $374,513,000 after acquiring an additional 1,251,199 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Sanofi by 2.3% in the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock valued at $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in shares of Sanofi by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 4,503,957 shares of the company’s stock valued at $223,982,000 after purchasing an additional 305,781 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a $1.478 dividend. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.